MDxHealth « Terug naar discussie overzicht

quote:

inspirator schreef op 15 juni 2016 17:01:

21 juni overname MdxHealth door Exact Sciences een feit

Exact Sciences: What the Heck is Going On?

By Ben Levisohn

Yesterday, shares of Exact Sciences (EXAS) surged for no reason at all. Today, they’re up another 7%–and we now know the reason for the stock’s big move. Canaccord Genuity’s Mark Massaro and Mary Kate Gorman explain:

We reiterate our BUY rating on Exact Sciences and raise our PT to $12 from $9. Around 10 pm ET or so on Tuesday (June 14), the USPSTF uploaded a 12-page recommendation statement that we believe bodes well for Exact Sciences. In the document, the USPSTF removed the words “recommended” and “alternative” and reiterated that “colorectal cancer screening” is an A rating, and clearly removed any hierarchy of test modalities. We spoke late last night with management, which is declining comment until the USPSTF formally announces these statements (press release) or when JAMA publishes these findings (June 21 on the Task Force document). We’ll let events play out over the next few days before we update out-year revenue estimates. Our raised PT to $12 now uses a 6.0x multiple on our unchanged 2018 revenue estimate of $250M, discounted back to the present at a 15% discount rate. Our view is that this is long-awaited great news for Exact Sciences, a decision we believe will trigger commercial payor mandates, notably from UnitedHealth Group (UNH) and Aetna (AET), to name two. The next key controversy likely turns to at what price the large payors will pay for Cologuard.

Remember, shares of Exact Sciences lost nearly half their value back in October after it was originally designated an “alternative.”

quote:

fly like an eagle schreef op 21 juni 2016 17:42:

Nou inspirator je hebt wel de langste dag uitgekozen dat het licht is dus we kunnen lang uitkijken naar die overname van over de plas. Maar daar is nog langer licht dus we gaat het zien -:)

quote:

William III of England schreef op 21 juni 2016 20:57:

Ho ho ho ik verwacht om 22.15 een overname van Mdx door Exas.
Je gaat nou toch niet weer lopen neuzelen kakelaar.

Boter bij de vis. Exas staat vet in de min dus gaat vanavond zeker de buidel trekken!

quote:

William III of England schreef op 21 juni 2016 21:11:

Ik wacht het nu wel af.

quote:

harryvanluik schreef op 23 juni 2016 21:53:

Inspirator. Kan je een stukje uit dat bericht kopiëren? Wij hebben geen toegang tot genomeWeb

quote:

inspirator schreef op 15 juni 2016 17:01:

21 juni overname MdxHealth door Exact Sciences een feit

Exact Sciences: What the Heck is Going On?

By Ben Levisohn

Yesterday, shares of Exact Sciences (EXAS) surged for no reason at all. Today, they’re up another 7%–and we now know the reason for the stock’s big move. Canaccord Genuity’s Mark Massaro and Mary Kate Gorman explain:

We reiterate our BUY rating on Exact Sciences and raise our PT to $12 from $9. Around 10 pm ET or so on Tuesday (June 14), the USPSTF uploaded a 12-page recommendation statement that we believe bodes well for Exact Sciences. In the document, the USPSTF removed the words “recommended” and “alternative” and reiterated that “colorectal cancer screening” is an A rating, and clearly removed any hierarchy of test modalities. We spoke late last night with management, which is declining comment until the USPSTF formally announces these statements (press release) or when JAMA publishes these findings (June 21 on the Task Force document). We’ll let events play out over the next few days before we update out-year revenue estimates. Our raised PT to $12 now uses a 6.0x multiple on our unchanged 2018 revenue estimate of $250M, discounted back to the present at a 15% discount rate. Our view is that this is long-awaited great news for Exact Sciences, a decision we believe will trigger commercial payor mandates, notably from UnitedHealth Group (UNH) and Aetna (AET), to name two. The next key controversy likely turns to at what price the large payors will pay for Cologuard.

Remember, shares of Exact Sciences lost nearly half their value back in October after it was originally designated an “alternative.”